Show simple item record

dc.contributor.authorStoker, Thomas
dc.contributor.authorTorsney, Kelli M
dc.contributor.authorBarker, Roger
dc.date.accessioned2018-12-04T00:30:33Z
dc.date.available2018-12-04T00:30:33Z
dc.date.issued2018
dc.identifier.issn1662-4548
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/286244
dc.description.abstractParkinson's disease (PD) is the second most common neurodegenerative disease, manifesting as a characteristic movement disorder with a number of additional non-motor features. The pathological hallmark of PD is the presence of intra-neuronal aggregates of α-synuclein (Lewy bodies). The movement disorder of PD occurs largely due to loss of dopaminergic neurons of the substantia nigra, resulting in striatal dopamine depletion. There are currently no proven disease modifying treatments for PD, with management options consisting mainly of dopaminergic drugs, and in a limited number of patients, deep brain stimulation. Long-term use of established dopaminergic therapies for PD results in significant adverse effects, and there is therefore a requirement to develop better means of restoring striatal dopamine, as well as treatments that are able to slow progression of the disease. A number of exciting treatments have yielded promising results in pre-clinical and early clinical trials, and it now seems likely that the landscape for the management of PD will change dramatically in the short to medium term future. Here, we discuss the promising regenerative cell-based and gene therapies, designed to treat the dopaminergic aspects of PD whilst limiting adverse effects, as well as novel approaches to reducing α-synuclein pathology.
dc.description.sponsorshipThe authors acknowledge financial support from the following organisations: Wellcome Trust Stem Cell Institute (Cambridge), Medical Research Council, National Institute for Health Research Biomedical Research Centre and the Cure Parkinson’s Trust.
dc.format.mediumElectronic-eCollection
dc.languageeng
dc.publisherFrontiers Media SA
dc.rightsAttribution 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.titleEmerging Treatment Approaches for Parkinson's Disease.
dc.typeArticle
prism.publicationDate2018
prism.publicationNameFront Neurosci
prism.startingPage693
prism.volume12
dc.identifier.doi10.17863/CAM.33557
dcterms.dateAccepted2018-09-18
rioxxterms.versionofrecord10.3389/fnins.2018.00693
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.licenseref.startdate2018-01
dc.contributor.orcidStoker, Thomas [0000-0001-5186-7630]
dc.contributor.orcidBarker, Roger [0000-0001-8843-7730]
dc.identifier.eissn1662-453X
rioxxterms.typeJournal Article/Review
pubs.funder-project-idMedical Research Council (MC_PC_12009)
cam.issuedOnline2018-10-08


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution 4.0 International
Except where otherwise noted, this item's licence is described as Attribution 4.0 International